Valinomycin

Research use only, not for human use.

Valinomycin is a cyclic depsipeptide antibiotic and a potassium-specific ionophore.Valinomycin induces PINK1 activation and promotes Parkin phosphorylation at Ser65.

Valinomycin is a cyclic depsipeptide antibiotic and a potassium-specific ionophore.Valinomycin induces PINK1 activation and promotes Parkin phosphorylation at Ser65.(In Vitro):Valinomycin significantly induced CHO cell death within 12 hours after administration. In CHO cells treated with valinomycin, within the first few hours, multiple apoptotic features were observed, including caspase-3 activation, phosphatidylserine (PS) membrane translocation, and mitochondrial membrane depolarization. Increasing the extracellular potassium concentration can reduce potassium efflux .(In Vivo):Valinomycin is irritating in contact with eyes and skin. Inhalation of Valinomycin can cause respiratory disturbances and even loss of consciousness. The median lethal dose (LD50) of Valinomycin in mice and rabbits was 2.5 mg/kg and 5 mg/kg, respectively. Valinomycin also has various chronic effects, including central and peripheral nervous system damage, eye damage, lens damage, and corneal damage .

——

Animal Model:nude mice with HepG2 Dosage:1, 2, 5, 10, 20, 40 μg/g Administration:Intravenous injection (i.v.), every two days for 16 d Result:Exerted remarkable inhibition effect on tumor growth and no weight loss during the therapeutic period. Caused destructive tumor necrosis as most of the tumor cells were in apoptotic status.

NSC 122023

Apoptosis

Apoptosis

Apoptosis

——

——

2001-95-8

1111.32

C54H90N6O18

>98% (HPLC)

In Vitro:?Ethanol : 50 mg/mL (44.99 mM)

CC(C)[C@H](C(O[C@@H](C)C(N[C@@H](C(C)C)C(O[C@H](C(C)C)C(N[C@H](C(C)C)C(O[C@@H](C)C(N[C@@H](C(C)C)C(O[C@H](C(C)C)C(N[C@H](C(C)C)C(O[C@@H](C)C(N[C@@H](C(C)C)C(O[C@@H]1C(C)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O

——

(-20℃)

With Ice Pack

≥ 2 years